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By providing clinicians, dealing with children with CKD, with more advanced and appropriate tools to improve management of all children with CKD, i.e. better assessment of 
the degree of renal dysfunction, better determination of the ideal time to start renal replacement therapy, and more accurate monitoring of the quality of that renal 
replacement therapy, we aim to improve neurocognitive and psychosocial functioning, growth, maturation into puberty, and social integration and survival.  
 
 
Children with chronic kidney disease have significant co-morbidities resulting in  
  a lifelong need for health care 
  3 times decreased life expectancy 
  poor quality of life and integration in society 
Good tools to evaluate severity and monitor adequacy of treatment of children 
with CKD are lacking resulting in suboptimal management.  
Retention of uraemic toxins is accepted to play a major role in the pathogenesis of 
the comorbid conditions, but studies in children are lacking.  
Background 
 
The scientific objective of this four years project is to: 
 
provide the clinician  
with new diagnostic and therapeutic tools  
for the management of children with chronic kidney disease 
 based on the improved understanding of  
URAEMIC TOXICITY 
 
Project funded by IWT and starting on the 1st of October 2015 
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Methods  
Development of the prescription simulator 
In vivo validation of kinetic model: 
Measuring TAC, TSR, Cpredialysis  
in patients on different dialysis strategies 
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• Patient characteristics 
• Uraemic toxin marker              
concentrations 
Model parameters: 
V1, V2, K12 
Cpredialysis 
PD strategy: dwell time, PD 
fluid, APD/CAPD 
 
HD strategy: sessions/week, 
session duration, HD/HDF 
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SIMULATION OUTPUT 
New 
strategy:  
 
 
TAC 
Cpredialysis 
Relations between marker 
concentrations/removal, patient 
characteristics, and PD strategies 
3. Validation of the kinetic models by evaluating uraemic toxin concentrations and 
co-morbidity variations after interventions (e.g.  optimal dialysis strategy as 
determined by the modelling) in PD and HD patients. 
4. Development of prediction simulator to determine the most optimal dialysis 
strategy in the individual patient, including the organisation of the ‘CKD academy’ 
for nephrologists and laboratory staff with workshops about the simulator and the 
related laboratory techniques. 
 
1. Identify associations between concentrations of a broad array of uraemic 
toxins and different co-morbidities: i.e growth, protein-energy wasting, 
cardiovascular risk factors, quality of life, circadian rhythm,  psycho-social 
functioning (cross-sectional & longitudinal) 
2. Evaluate kinetic modelling of uraemic toxin distribution and transport in 
haemodialysis (HD) patients 
IDENTIFICATION OF THE MOST  
REPRESENTATIVE URAEMIC TOXIN MARKER(S) 
